rituximab,epcoritamab
roche,genmab,abbvie,janssen,biogen
['epcoritamab', 'epcore,nhl,2', 'lymphoma', 'nhl', 'epcore nhl-2', 'lymsm']
in the epcore nhl-2 trial, #epcoritamab therapy was manageable and achieved high rates of response in patients with high-risk diffuse large b-cell #lymphoma. #lymsm #asco22 
Oncology news and insights from leading researchers and cancer centers.